Refers to New aminopirazoloquinazolinas of formula (i) wherein R1 is H, alkyl of C1 - C6, alquenilo C2 - C6, alquinilo C2 - C6 among others R2 is H, alkyl of C1 - C6, alquenilo C2 - C6, alquinilo C2 - C6 C10 cycloalkyl, C3, R3 is among others (ii) (iii) where a is an aryl heteroaryl C5 C6 C10 and C12 b Its not a heteroaryl - C7 Aromatic C5 with at least a heteroatom selected from Group n, s and o,R4 and R5 are selected from the Group ra and RB, ra is a c1-c6 alkyl, alquenilo C2 - C6 among others RB is Halogen, - CN, - NO2, among others M is 0,1,2, y3 n is 0 OR 1 X is - CH2 - and - CH2 - CH2 - among others.Preferred compounds are (5S) - N - [1 - (2-methoxyethyl) pyrazole - 3 - yl] - 5.8 - dimethyl - 9 - phenyl - 5.6 - 3.4 - dihidropirazolo [h] - 2 - quinazolin Amine, N - [1 - (2 - dimetilaminoetil) pyrazole - yl] - 3 - 5.8 - Dimethyl - 9 - phenyl - 5.6 - 3.4 - dihidropirazolo [h] - 2 - quinazolin Amine, among others. It also relates to a Pharmaceutical formulation.These compounds are useful for the treatment of non small-cell bronchial carcinomas and carcinomas hepatociticos.SE REFIERE A NUEVAS AMINOPIRAZOLOQUINAZOLINAS DE FORMULA (I) DONDE R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6 ENTRE OTROS R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, CICLOALQUILO C3-C10, ENTRE OTROS R3 ES (II) , (III) DONDE A ES UN ARILO C6-C10 Y HETEROARILO C5-C12 B ES UN HETEROARILO NO AROMATICO C5-C7 CON AL MENOS UN HETEROATOMO SELECCIONADO DEL GRUPO N, S Y O, R4 Y R5 ESTAN SELECCIONADOS DEL GRUPO Ra y Rb, Ra ES UN ALQUILO C1-C6, ALQUENILO C2-C6 ENTRE OTROS Rb ES HALOGENO, -CN, -NO2 ENTRE OTROS m es 0,1,2,y3 n ES 0 Y 1 X ES -CH2- Y -CH2-CH2- ENTRE OTROS. SON COMPUESTOS PREFERIDOS (5S)-N-[1-(2-METOXIETIL) PIRAZOL-3-IL]-5,8-DIMETIL-9-FENIL-5,6-DIHIDROPIRAZOLO[3,4-H]-QUINAZOLIN-2-AMINA, N-[1-(2-DIMETILAMINOETIL)PIRAZOL-3-IL]-5,8-DIMETIL-9-FENIL-5,6-DIHIDROPIRAZOLO[3,4-H]-QUINAZOLIN-2-AMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA. DICHOS COMPUEST
